oncolytic adenovirus expressing GMCSF
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bladder Cancer
Conditions
Bladder Cancer, High Grade, Non Muscle Invasive
Trial Timeline
Mar 1, 2014 → Mar 1, 2015
NCT ID
NCT02143804About oncolytic adenovirus expressing GMCSF
oncolytic adenovirus expressing GMCSF is a phase 2 stage product being developed by CG Oncology for Bladder Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02143804. Target conditions include Bladder Cancer, High Grade, Non Muscle Invasive.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02143804 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Bladder Cancer